4//SEC Filing
Mattes Glenn R. 4
Accession 0001213900-21-003298
CIK 0001733413other
Filed
Jan 19, 7:00 PM ET
Accepted
Jan 20, 8:37 PM ET
Size
10.6 KB
Accession
0001213900-21-003298
Insider Transaction Report
Form 4
Mattes Glenn R.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2021-01-15$2.50/sh+40,000$100,000→ 50,000 total - Sale
Common Stock
2021-01-15$17.51/sh−40,000$700,400→ 10,000 total - Sale
Common Stock
2020-09-25$17.00/sh−3,000$51,000→ 7,000 total(indirect: By Spouse) - Exercise/Conversion
Stock Options (Right to Buy)
2021-01-15−40,000→ 1,034,227 totalExercise: $2.50From: 2019-05-01Exp: 2028-05-01→ Common Stock (40,000 underlying)
Footnotes (3)
- [F1]The transactions reported by this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2020.
- [F2]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F3]200,000 shares of the option vested and became exercisable on May 1, 2019.
Documents
Issuer
TFF Pharmaceuticals, Inc.
CIK 0001733413
Entity typeother
Related Parties
1- filerCIK 0001568678
Filing Metadata
- Form type
- 4
- Filed
- Jan 19, 7:00 PM ET
- Accepted
- Jan 20, 8:37 PM ET
- Size
- 10.6 KB